GLP-1 drugs cut kidney failure risk by 16%, not just heart attacks

GLP-1 receptor agonists have become some of the most widely discussed drugs in medicine, prescribed for type 2 diabetes and increasingly for weight management. Large trials had already established that they reduce major adverse cardiovascular events such as heart attack and stroke. What remained genuinely uncertain was whether they also protect the kidneys in ways that matter clinically, meaning fewer people progressing to kidney failure rather than just favourable shifts in laboratory markers. Because kidney disease so often travels alongside diabetes and heart disease, settling that question changes how the whole drug class is judged.

The researchers pooled randomised controlled trials that compared a GLP-1 receptor agonist with placebo, enrolled at least 500 participants with type 2 diabetes and followed them for at least 12 months, searching the literature up to March 26, 2024. They also added the SELECT trial, which enrolled people with cardiovascular disease and a BMI of 27 or more but without diabetes. Eleven trials covering 85 373 participants made the cut, 29 386 of them women. The main kidney outcome combined kidney failure, a sustained drop in kidney filtration of at least 50%, or death from kidney failure, assessed alongside major adverse cardiovascular events.

Among participants with type 2 diabetes, GLP-1 receptor agonists reduced the composite kidney outcome by 18% compared with placebo, kidney failure by 16%, major cardiovascular events by 13% and death from any cause by 12%. Adding the SELECT trial, whose participants did not have diabetes, barely changed these figures, suggesting the benefits are not confined to diabetes. Serious adverse events, including acute pancreatitis and severe hypoglycaemia, were no more common on the drugs than on placebo. However, people taking a GLP-1 receptor agonist stopped treatment because of adverse events more often than those on placebo.

This analysis confirms the established cardiovascular benefit of GLP-1 receptor agonists and extends the evidence to clinically important kidney outcomes, where the picture had been uncertain. The consistency between the diabetes trials and the one trial in people without diabetes hints that the protection may generalise beyond diabetes, though a single trial cannot settle that. Open questions remain about how the drugs protect the kidneys, how they compare with other kidney-protective treatments, and how tolerability shapes long-term use outside the discipline of a clinical trial.

For anyone with type 2 diabetes, or supporting someone who has it, this is a reason to see GLP-1 receptor agonists as more than blood sugar or weight drugs: the pooled trial record now links them to fewer serious kidney events, fewer cardiovascular events and fewer deaths. It is equally worth knowing that more trial participants on the drugs stopped because of side effects, so the benefits sit alongside genuine tolerability issues. These are prescription medicines, and the right call for any individual is a conversation with a clinician, not a headline.